Reading the tape
NASDAQ: GRAL
GRAIL, Inc.
Healthcare · Medical - Diagnostics & Research
Market Cap
$2.28B
52w High
$118.84
52w Low
$29.95
P/E
-5.55
Volume
482.57K
Outstanding Shares
41.02M
Price vs Fundamentals
Why The Stock Is Moving
Fundamentals are supporting the moveModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 62.46%Revenue (TTM): 17.18%FCF (TTM): 48.66%
What changed
The stock rose 62.46% over the last year. Revenue grew 17.18% over the trailing twelve months. Operating margin moved from -1,743.03% to -381.98%. Free cash flow grew 48.66% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum. The operating data is doing enough work that the move does not need an overvaluation story to explain it.
What would invalidate this read
Operating margin is at -381.98%. Revenue grew 17.18% — this thesis depends on that trajectory holding. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Company profile
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection.
CEORobert Ragusa
SectorHealthcare
IndustryMedical - Diagnostics & Research
Employees1,000
IPO dateJun 12, 2024
Valuation
Forward P/E—
EV/EBITDA-7.92
Enterprise value$2.99B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth13.97%
Gross margin-42.52%▲31.56%vs FY2024
Operating margin-381.98%▲79.18%vs FY2024
ROE-15.84%▲80.44%vs FY2024
Analyst consensus
RatingBuy
Target price$77.33▲38.93%
3
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 5, 2026
Q2 FY26 · EPS est -$2.76 · Revenue est $39.16M
View